We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

116 hedge funds and large institutions have $667M invested in Eagle Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 45 increasing their positions, 28 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 28

54% more call options, than puts

Call options by funds: $11.6M | Put options by funds: $7.55M

4% more capital invested

Capital invested by funds: $640M → $667M (+$27.1M)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

8% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 26

3% less funds holding

Funds holding: 119 → 116 (-3)

Holders
116
Holders Change
-3
Holders Change %
-2.52%
% of All Funds
3.09%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
24
Increased
45
Reduced
28
Closed
26
Calls
$11.6M
Puts
$7.55M
Net Calls
+$4.09M
Net Calls Change
-$19.8M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$43.1M
2
Morgan Stanley
Morgan Stanley
New York
+$28.8M
3
GPP
Great Point Partners
Connecticut
+$22.8M
4
HEC
Hudson Executive Capital
New York
+$22M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.66M

Top Sellers

Rank Fund Capital Flow
1
PWAM
Park West Asset Management
California
-$35.1M
2
JAM
JW Asset Management
Florida
-$9.78M
3
CCM
Consonance Capital Management
New York
-$8.82M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.85M
5
State Street
State Street
Massachusetts
-$7.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Asset Management One
26
Asset Management One
Japan
$3.88M -$218K -5,247 -5%
CWG
27
C WorldWide Group
Denmark
$3.78M -$4.23M -101,500 -51%
ARTA
28
A.R.T. Advisors
New York
$3.26M +$3.5M +84,039 New
GH
29
GAM Holding
Switzerland
$3.13M +$908K +21,800 +37%
PAM
30
Panagora Asset Management
Massachusetts
$3.08M +$127K +3,038 +4%
QI
31
QS Investors
New York
$2.96M – – –
Deutsche Bank
32
Deutsche Bank
Germany
$2.62M +$1.85M +44,361 +192%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$2.61M -$51.1K -1,226 -2%
William Blair & Company
34
William Blair & Company
Illinois
$2.57M +$38.5K +925 +1%
WRF
35
Waddell & Reed Financial
Kansas
$2.17M +$496K +11,900 +27%
CS
36
Candriam SCA
Luxembourg
$2.13M -$104K -2,500 -4%
OM
37
Opaleye Management
Massachusetts
$1.94M -$416K -10,000 -17%
Parallax Volatility Advisers
38
Parallax Volatility Advisers
California
$1.74M +$696K +16,721 +60%
HCMT
39
Highland Capital Management (Texas)
Texas
$1.68M -$736K -17,681 -29%
CS
40
Credit Suisse
Switzerland
$1.63M -$897K -21,531 -34%
GC
41
Guggenheim Capital
Illinois
$1.62M +$208K +5,005 +14%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.61M +$27.4K +658 +2%
IA
43
Icon Advisers
Colorado
$1.59M +$1.71M +41,000 New
PAMP
44
Polar Asset Management Partners
Ontario, Canada
$1.55M +$1.67M +40,000 New
WSA
45
Wall Street Associates
California
$1.36M – – –
Lazard Asset Management
46
Lazard Asset Management
New York
$1.29M +$1.39M +33,400 New
BIM
47
BlackRock Investment Management
Delaware
$1.27M +$148K +3,548 +12%
AQR Capital Management
48
AQR Capital Management
Connecticut
$1.2M -$191K -4,577 -13%
Charles Schwab
49
Charles Schwab
California
$1.19M +$21.2K +510 +2%
TCIM
50
TIAA CREF Investment Management
New York
$1.02M -$4.46K -107 -0.4%
1
2
3 4 5

EGRX Hedge Fund Activity: Q2 2016 in Review

116 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2016, worth a combined $667M — up 4.2% from $640M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of EGRX and 24 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 45 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $43.1M. The largest seller was Park West Asset Management, cutting an estimated $35.1M.

  • 116 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2016, down from 119 in Q1 2016.
  • Funds reported $667M of Eagle Pharmaceuticals, Inc. stock for Q2 2016, up 4.2% quarter-over-quarter.
  • 24 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2016 and 26 closed out, a net change of -2 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2016 was OrbiMed, an estimated $43.1M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q2 2016 was Park West Asset Management, an estimated $35.1M sold.

Based on aggregated 13F filings for Q2 2016.